AlphaCrest Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

AlphaCrest Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-53,151	Closed	-$698K	–	1316
2020 Q4	$698K	Buy	53,151 +1,521	+3%	+$18.3K	0.06%	475
2020 Q3	$499K	Buy	51,630 +33,212	+180%	+$355K	0.05%	591
2020 Q2	$211K	Sell	18,418 -17,800	-49%	-$202K	0.04%	821
2020 Q1	$375K	Buy	36,218 +13,307	+58%	+$165K	0.05%	701
2019 Q4	$376K	Sell	22,911 -28,989	-56%	-$438K	0.03%	947
2019 Q3	$689K	Buy	+51,900	New	+$723K	0.04%	765
2019 Q2	–	Sell	-25,900	Closed	-$477K	–	1144
2019 Q1	$477K	Buy	+25,900	New	+$590K	0.07%	480

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

AlphaCrest Capital Management's VNDA Position: Q1 2021 in Review

AlphaCrest Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2021, closing a stake of 53,151 shares — an estimated $698K sold.

AlphaCrest Capital Management first reported a position in VNDA in Q1 2019 and held it in 7 quarters. The position peaked at $698K in Q4 2020. 189 funds tracked by Wall St. Rank hold VNDA as of Q1 2021.

AlphaCrest Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
AlphaCrest Capital Management sold 53,151 Vanda Pharmaceuticals shares in Q1 2021, an estimated $698K.
AlphaCrest Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2019 and held it in 7 quarters.
AlphaCrest Capital Management's Vanda Pharmaceuticals position peaked at $698K in Q4 2020.
189 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2021.

Based on AlphaCrest Capital Management's 13F filing for Q1 2021, filed 13 May 2021.